Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.
作者： Jennifer Rachel Eads , Smitha S. Krishnamurthi , Joel N. Saltzman , David Lawrence Bajor , Shaveta Vinayak
DOI: 10.1200/JCO.2018.36.15_SUPPL.2562
关键词:
摘要: 2562Background: Colorectal cancers (CRCs) harboring a PIK3CA mutation demonstrate glutamine dependency in both vitro and vivo models, including those known to be fluoropyrimidine (FP) resista...
sci-hub.st 参考文章(0)